Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)

被引:174
作者
Roos, DE [1 ]
Turner, SL
O'Brien, PC
Smith, JG
Spry, NA
Burmeister, BH
Hoskin, PJ
Ball, DL
机构
[1] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[2] Westmead Hosp, Westmead, NSW, Australia
[3] Newcastle Mater Misericordiae Hosp, Newcastle, NSW, Australia
[4] Peter MacCallum Canc Inst, Ctr Stat, Melbourne, Australia
[5] Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia
[6] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia
[7] Mt Vernon Hosp, Marie Curie Res Wing, Northwood HA6 2RN, Middx, England
[8] Peter MacCallum Canc Ctr, Melbourne, Australia
关键词
bone metastases; neuropathic pain; radiotherapy; randomized trial;
D O I
10.1016/j.radonc.2004.09.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Despite numerous randomized trials investigating radiotherapy (RT) fractionation schedules for painful bone metastases, there are very few data on RT for bone metastases causing pain with a neuropathic component. The Trans-Tasman Radiation Oncology Group undertook a randomized trial comparing the efficacy of a single 8 Gy (8/1) with 20 Gy in 5 fractions (20/5) for this type of pain. Materials and methods: Eligible patients had radiological evidence of bone metastases from a known malignancy with no change in systemic therapy within 6 weeks before or anticipated within 4 weeks after RT, no other metastases along the distribution of the neuropathic pain and no clinical or radiological evidence of cord/cauda equina compression. All patients gave written informed consent. Primary endpoints were pain response within 2 months of commencement of RT and time to treatment failure (TTF). The hypothesis was that 8/1 is at least as effective as 20/5 and the planned sample size was 270 patients. Results: Between February 1996 and December 2002, 272 patients were randomized (8/1:20/5 = 137:135) from 15 centres (Australia 11, New Zealand 3, UK 1). The commonest primary cancers were lung (31%), prostate (29%) and breast (8%); index sites were spine (89%), rib (9%), other (2%); 72% of patients were males and the median age was 67 (range 2989). The median overall survival (95% CI) for all randomized patients was 4.8 mo (4.2-5.7 mo). The intention-to-treat overall response rates (95% Cl) for 8/1 vs 20/5 were 53% (45-62%) vs 61% (53-70%), P = 0.18. Corresponding figures for complete response were 26% (18-34%) vs 27% (19-35%), P = 0.89. The estimated median TTFs (95% CI) were 2.4 mo (2.0-3.3 mo) vs 3.7 mo (3.1-5.9 mo) respectively. The hazard ratio (95% Cl) for the comparison of TTF curves was 1.35 (0.99-1.85), log-rank P = 0.056. There were no statistically significant differences in the rates of re-treatment, cord compression or pathological fracture by arm. Conclusions: 8/1 was not shown to be as effective as 20/5, nor was it statistically significantly worse. Outcomes were generally poorer for 8/1, although the quantitative differences were relatively small. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:54 / 63
页数:10
相关论文
共 21 条
[11]  
Moher D., 2001, The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials
[12]   MULTIPLE TESTING PROCEDURE FOR CLINICAL-TRIALS [J].
OBRIEN, PC ;
FLEMING, TR .
BIOMETRICS, 1979, 35 (03) :549-556
[13]   PROSPECTIVE RANDOMIZED TRIAL OF SINGLE AND MULTIFRACTION RADIOTHERAPY SCHEDULES IN THE TREATMENT OF PAINFUL BONY METASTASES [J].
PRICE, P ;
HOSKIN, PJ ;
EASTON, D ;
AUSTIN, D ;
PALMER, SG ;
YARNOLD, JR .
RADIOTHERAPY AND ONCOLOGY, 1986, 6 (04) :247-255
[14]   Radiotherapy for painful bone metastases: an overview of the overviews (vol 15, pg 342, 2003) [J].
Roos, DE ;
Fisher, RJ .
CLINICAL ONCOLOGY, 2003, 15 (08) :509-509
[15]   Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05) [J].
Roos, DE ;
Davis, SR ;
Turner, SL ;
O'Brien, PC ;
Spry, NA ;
Burmeister, BH ;
Hoskin, PJ ;
Ball, DL .
RADIOTHERAPY AND ONCOLOGY, 2003, 67 (02) :207-212
[16]   A role for radiotherapy in neuropathic bone pain: Preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96.05) [J].
Roos, DE ;
O'Brien, PC ;
Smith, JG ;
Spry, NA ;
Hoskin, PJ ;
Burmeister, BH ;
Turner, SL ;
Bernshaw, DM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (04) :975-981
[17]   Continuing reluctance to use single fractions of radiotherapy for metastatic bone pain: an Australian and New Zealand practice survey and literature review [J].
Roos, DE .
RADIOTHERAPY AND ONCOLOGY, 2000, 56 (03) :315-322
[18]  
ROSS DE, 2000, AUSTRALAS RADIOL, V44, P303
[19]   Palliation of metastatic bone pain: Single fraction versus multifraction radiotherapy - A systematic review of randomised trials [J].
Sze, WM ;
Shelley, MD ;
Held, I ;
Wilt, TJ ;
Mason, MD .
CLINICAL ONCOLOGY, 2003, 15 (06) :345-352
[20]   Neuropathic pain: aetiology, symptoms, mechanisms, and management [J].
Woolf, CJ ;
Mannion, RJ .
LANCET, 1999, 353 (9168) :1959-1964